Biomarkers in tongue cancer: Understanding the molecular basis and their clinical implications

Postgraduate Medical Journal

Volumn 86, Issue 1015, 2010, Pages 292-298

  Zheng, Min ^a   Li, Li ^a   Tang, Ya Ling ^a   Liang, Xin Hua ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CEDIRANIB; CETUXIMAB; CISPLATIN; CYTOKERATIN; CYTOKINE; DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; LIDOCAINE; MATRIX METALLOPROTEINASE; MESSENGER RNA; ONYX 015; PERIFOSINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53; PROTEINASE; RECOMBINANT ADENOVIRUS P53; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UROKINASE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; WART VIRUS VACCINE;

ADD ON THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL TRANSFORMATION; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HYPOXIA; LUNG NON SMALL CELL CANCER; MESENCHYME CELL; METASTASIS; MOUTH CANCER; ONCOGENE; ONCOGENE C FOS; ONCOGENE C JUN; ONCOGENE C MYC; PREDICTION; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TONGUE CANCER; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VIRUS INFECTION;

CELL HYPOXIA; CYTOKINES; GENES, TUMOR SUPPRESSOR; HUMANS; KERATINS, HAIR-SPECIFIC; MATRIX METALLOPROTEINASES; PROTO-ONCOGENES; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953700470     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.086504     Document Type: Review

References (124)

1. Yang TL, Wang CP, Ko JY, et al. Association of tumor satellite distance with prognosis and contralateral neck recurrence of tongue squamous cell carcinoma. Head Neck 2008;30:631-8.
2. Myers JN, Holsinger FC, Jasser SA, et al. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002;8:293-8.
3. Wulong J, Zhou L, Xiaojian Z, et al. Establishment of a highly metastatic tongue squamous cell carcinoma cell line from New Zealand White rabbit. Arch Oral Biol 2008;53:1084-90.
4. Jin WL, Ye WM, Zheng JW, et al. Occult cervical lymph node metastases in 100 consecutive patients with cN0 tongue cancer. Chin Med J (Engl) 2008;121:1871-4.
5. Liao CT, Wang HM, Hsieh LL. Higher distant failure in young age tongue cancer patients. Oral Oncol 2006;42:718-25.
6. Gorsky M, Epstein JB, Oakley C, et al. Carcinoma of the tongue: a case series analysis of clinical presentation, risk factors, staging, and outcome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:546-52.
7. Sato T. [A study on effect of mechanical irritation in development and progression of tongue cancer](In Japanese). Kokubyo Gakkai Zasshi 1995;62:532-50.
8. Ekberg T, Nestor M, Engström M, et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 2005;26:1177-85.
9. Vora HH, Trivedi TI, Shukla SN, et al. p53 expression in leukoplakia and carcinoma of the tongue. Int J Biol Markers 2006;21:74-80. (Pubitemid 44210035)
10. Kuremsky JG, Tepper JE, McLeod HL, et al. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009;74:673-88.
11. Katayama K, Shibata K, Mitsuhashi J, et al. Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling. Anitcancer Res 2009;29:1059-65.
12. Sienmann DW, Norris CM, Ryan A, et al. Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer Res 2009;29:1987-92.
13. Wen SF, Mahavni V, Quijano E, et al. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther 2003;10:224-38.
14. Failes TW, Hambley TW. Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat. J Inorg Biochem 2007;101:396-403.
15. Friedman WH, Rosenblum B, Loewenstein P, et al. Oncogenes: preliminary studies in head and neck cancer. Laryngoscope 1983;93:1441-4.
16. Elledge R. Current concepts in research related to oncogenes implicated in salivary gland tumourigenesis: a review of the literature. Oral Dis 2009;15:249-54.
17. Riva C, Lavieille JP, Reyt E, et al. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer B Oral Oncol 1995;31:384-91.
18. Li Z, Boone D, Hann SR. Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci U S A 2008;105:18794-9.
19. Vora HH, Shah NG, Trivedi TI, et al. Expression of C-Myc mRNA in squamous cell carcinoma of the tongue. J Surg Oncol 2007;95:70-8.
20. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008;455:679-83.
21. Turatti E, da Costa Neves A, de Magalhães MH, et al. Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant oral lesions. J Oral Sci 2005;47:71-6.
22. Mahner S, Baasch C, Schwarz J, et al. C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 2008;99:1269-75.
23. Ohyama M, Hirayama Y, Tanuma J, et al. Expressions of junB and c-fos are enhanced in 4-nitroquinoline 1-oxide-induced rat tongue cancers. Pathol Int 2004;54:35-40. (Pubitemid 38979580)
24. de Sousa SO, Mesquita RA, Pinto DS Jr, et al. Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. J Oral Pathol Med 2002;31:78-81. (Pubitemid 34535991)
25. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 2003;127:930-4.
26. D' Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
27. Haddad R, Crum C, Chen Z, et al. HPV16 transmission between a couple with HPV-related head and neck cancer. Oral Oncol 2008;44:812-15.
28. Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005;32:S59-66.
29. Dahlgren L, Erlandsson F, Lindquit D, et al. Differences in human papillomavirus type may influence clinical outcome in early stage cervical cancer. Anticancer Res 2006;26:829-32.
30. Tezal M, Sullivan Nasca M, Stoler DL, et al. Chronic periodontitis-human papillomavirus synergy in base of tongue cancers. Arch Otolaryngol Head Neck Surg 2009;135:391-6.
31. Liang XH, Lewis J, Foote R, et al. Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience. J Oral Maxillofac Surg 2008;66:1875-80.
32. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008;26(Suppl 1):A16-23.
33. Michalová K, Zemanová Z. [Molecular cytogenetics in diagnostics of malignant diseases] (In Czech). Cas Lek Cesk 2006;145:532-7.
34. Berbeć H. [Antioncogenesetumor suppression genes] (In Polish). Postepy Hig Med Dosw 1997;16:325e32.
35. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-21.
36. Liao XB, Hu DX, Zhou XM, et al. [Expression of PTEN, p16, p21, and p53 proteins in lung cancer using tissue microarray and their clinical significance] (In Chinese). Ai Zheng 2004;23:334-8.
37. Gartel AL. Transcriptional inhibitors, p53 and apoptoss. Biochim Biophys Acta 2008;1786:83-6.
38. Kozomara R, JovićN, Magić Z, et al. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. J Craniomaxillofac Surg 2005;33:342-8.
39. Kusama K, Okutsu S, Takeda A, et al. p53 gene alternations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J Pathol 1996;178:415-21.
40. Shirai N, Tsukamoto T, Yamamoto M, et al. Tongue carcinogenic susceptibility of p53 deficient mice to methyl-n-amylnitrosamine. J Toxicol Pathol 2002;15:209-14.
41. Tian G, Liu J, Chen W, et al. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs 2009;20:389-95.
42. Guan YS, Liu Y, He Q, et al. Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up. J Zhejiang Univ Sci B 2009;10:331-40.
43. Ganly I, Soutar DS, Kaye SB. Current role of gene therapy in head and neck cancer. Eur J Surg Oncol 2000;26:338-43.
44. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000;60:6359-66.
45. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
46. Hou P, Ji M, Ge C, Shen J, et al. Detection of methylation of human p16(Ink4a) gene 5′-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res 2003;31:E92.
47. Ivanova TA, Golovina DA, Zavalishina LE, et al. Up-regulation of expression and lack of 5' CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas. BMC Cancer 2007;7:47.
48. Nakahara Y, Shintani S, Mihara M, et al. Detection of p16 promoter methylation in the serum of oral cancer patients. Int J Oral Maxillofac Surg 2006;35:362-5.
49. Ogawa K, Tanuma J, Hirano M, et al. Selective loss of resistant alleles at p15INK4B and p16INK4A genes in chemically-induced rat tongue cancers. Oral Oncol 2006;42:710-17.
50. Nakazawa K, Murata S, Yuminamochi T, et al. p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. Am J Clin Pathol 2009;132:776-84.
51. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 2008;27:5416-30.
52. Snaddon J, Parkinson EK, Craft JA, et al. Detection of functional PTEN lipid phosphatase protein and enzyme activity in squamous cell carcinomas of the head and neck, despite loss of heterozygosity at this locus. Br J Cancer 2001;84:1630-4.
53. Fruman DA, Meyer RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481-507.
54. Shao X, Tandon R, Samara G, et al. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer 1998;77:684-8.
55. Lee JI, Soria JC, Hassan KA, et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 2001;127:1441-5.
56. Yang PL, Liu YH, Cui Y, et al. [Adenoviral-mediated expression of PTEN cDNA induces apoptosis in endometrial carcinoma cells] (In Chinese). Zhonghua Fu Chan Ke Za Zhi 2006;41:549-53.
57. Saito Y, Swanson X, Mhashikar AM, et al. Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther 2003;10:1961-9.
58. Pappas G, Zumstein LA, Munshi A, et al. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther 2007;14:543-9.
59. Massarelli E, Liu DD, Lee JJ, et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005;104:2430-6.
60. Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006;5:766-70.
61. Sheu BC, Chang WC, Cheng CY, et al. Cytokine regulation networks in the cancer microenvironment. Front Biosci 2008;13:6255-68.
62. Guo B, Zhang Y, Luo G, et al. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma. Anat Rec (Hoboken) 2009;292:633-9.
63. Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65.
64. Shao Z, Zhang WF, Chen XM, et al. Expression of EphA2 and VEGF in Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcomesquamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol 2008;44:1110-17.
65. Kim SH, Cho NH, Kim K, et al. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. J Surg Oncol 2006;93:330-7.
66. Tanigaki Y, Nagashima Y, Kitamura Y, et al. The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int J Mol Med 2004;14:389-95.
67. Hanrahan EO, Ryan AJ, Mann H, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009;15:3600-9.
68. Merseburger AS, Simon A, Waalkes S, et al. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2009;9:1429-34.
69. Meijerink MR, van Cruijsen H, Hoekman K, et al. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 2007;17:1700-13.
70. Wilson KJ, Gilmore JL, Foley J, et al. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 2009;122:1-8.
71. Hudson LG, Moss NM, Stack MS. EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. Future Oncol 2009;5:323-38.
72. Ryott M, Wangsa D, Heselmeyer-Haddad K, et al. EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. Eur J Cancer 2009;45:1700-8.
73. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
74. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54.
75. Kim YH, Mio T, Mishima M. Gefitinib for non-small cell lung cancer patients with liver cirrhosis. Intern Med 2009;48:1677-9.
76. Shintani S, Li C, Mihara M, et al. Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett 2003;201:149-55.
77. Sakaguchi M, Kuroda Y, Hirose M. The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth Analg 2006;102:1103-7.
78. Wang X, Sun W, Bai J, et al. Growth inhibition induced by transforming growth factor-beta1 in human oral squamous cell carcinoma. Mol Biol Rep 2009;36:861-9.
79. Sun L, Diamond ME, Ottaviano AJ, et al. Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res 2008;6:10-20. (Pubitemid 351378162)
80. Liu X, Gao Y. [The role of TGF-beta on Tca83ea tongue squamous cell carcinoma cell line] (In Chinese). Zhonghua Kou Qiang Yi Xue Za Zhi 2001;36:376-8.
81. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr, et al. Tumor metastasis in an orthotopic murine model of head and neck cancer: possible role of TGF-beta 1 secreted by the tumor cells. J Cell Biochem 2006;97:1036-51.
82. Ho YT, Yang JS, Li TC, et al. Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9. Cancer Lett 2009;279:155-62.
83. Oku N, Sasabe E, Ueta E, et al. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 2006;66:5251-7.
84. Guttman D, Stern Y, Shpitzer T, et al. Expression of MMP-9, TIMP-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue. Oral Oncol 2004;40:789-803. (Pubitemid 39061095)
85. Rand L, Green JA, Saraiva L, et al. Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPK-dependent, p-aminosalicylic acid-sensitive signaling cascade. J Immunol 2009;182:5865-72.
86. Shimizu Y, Kondo S, Shirai A, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer. Auris Nasus Larynx 2008;35:381-9.
87. Yoshizaki T, Maruyama Y, Sato H, et al. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 2001;95:44-50.
88. Nyberg P, Moilanen M, Paju A, et al. MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. J Dent Res 2002;81:831-5.
89. Korpi JT, Kervinen V, Mäklin H, et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer 2008;98:766-75.
90. Nyberg P, Heikkilä P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003;278:22404-11.
91. Skipper JB, McNally LR, Rosenthal EL, et al. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. ORL J Otorhinolaryngol Relat Spec 2009;71:1-5.
92. Lee SY, Chung SM. Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2 alpha suppression. Vascul Pharmacol 2007;47:313-18.
93. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43.
94. Hildenbrand R, Schaaf A, Dorn-Beineke A, et al. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009;24:869-77.
95. Liang X, Xiao G, Mao Z. [The effect of heat shock on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cell line (Tca8113)] (In Chinese). Hua Xi Kou Qiang Yi Xue Za Zhi 2003;21:150-2.
96. Liang X, Yang X, Tang Y, et al. RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. Oral Oncol 2008;44:1172-80.
97. Zhou H, Tang Y, Liang X, et al. RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma. Int J Cancer 2009;125:453-62.
98. Pilat MJ, Lehr JE, Quiqley MM, et al. The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model. Oncol Rep 1998;5:889-92.
99. Evans DM, Sloan-Stakleff K. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Am Surg 2000;66:460-4.
100. Mlodzik-Danielewicz N, Tyrakowski T. Effects of amiloride and bumetanide on hyperpolarization after movement across the distal colon epithelium. Pharmacol Rep 2005;57:489-97.
101. Kizaka-Kondoh S, Inoue M, Harada H, et al. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003;94:1021-8.
102. Yao H, Wang H, Zhang Z, et al. Sulforaphane inhibited expression of hypoxiainducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 2008;123:1225-61.
103. Otrock ZK, Hatoum HA, Awada AH, et al. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 2009;70:93-102.
104. Liang X, Yang D, Hu J, et al. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 2008;28:1659-66.
105. Roh JL, Cho KJ, Kwon GY, et al. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol 2009;45:63-8.
106. Loboda A, Stachurska A, Dorosz J, et al. HIF-1 attenuates Ref-1 expression in endothelial cells: reversal by siRNA and inhibition of geranylgeranylation. Vascul Pharmacol 2009;51:133-9.
107. Zhang Q, Zhang ZF, Rao JY, et al. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 2004;111:849-57.
108. Xu J, Wang R, Xie ZH, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006;66:1664-73.
109. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28:15-33.
110. Onoue T, Uchida D, Begum NM, et al. Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol 2006;29:1133-8.
111. Howard EW, Camm KD, Wong YC, et al. E-cadherin upregulation as a therapeutic goal in cancer treatment. Mini Rev Med Chem 2008;8:496-518.
112. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009;28:151-66.
113. Hoteiya T, Hayashi E, Satomura K, et al. Expression of E-cadherin in oral cancer cell lines and its relationship to invasiveness in SCID mice in vivo. J Oral Pathol Med 1999;28:107-11.
114. Diniz-Freitas M, García-Caballero T, Antúnez-López J, et al. Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol 2006;42:190-200. (Pubitemid 43106884)
115. Chang HW, Chow V, Lam KY, et al. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 2002;94:386-92.
116. Chow V, Yuen AP, Lam KY, et al. A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol 2001;172:59-63. (Pubitemid 32128515)
117. Diamond ME, Sun L, Ottaviano AJ, et al. Differential growth factor regulation of N-cadherin expression and motility in normal and malignant oral epithelium. J Cell Sci 2008;121:2197-207.
118. Duan L, Yao J, Wu X, Fan M, et al. Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell 2006;98:479-90.
119. Li S, Jiao J, Lu Z, et al. An essential role for N-cadherin and beta-catenin for progression in tongue squamous cell carcinoma and their effect on invasion and metastasis of Tca8113 tongue cancer cells. Oncol Rep 2009;21:1223-33.
120. Taweevisit M, Isarakul P, Chaipipat M, et al. Cytokeratin 7 and 20 as immunohistochemical markers in identification of primary tumors in craniospinal metastases: do they have a significant role? Neuropathology 2002;23:271-4.
121. Di Carlo A, Terracciano D, Mariano A, et al. Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors. Int J Oncol 2003;23:757-62.
122. Hayashi K, Yamamoto T, Oyama K, et al. Epidermotropic skin metastasis from gastric cancer: immunohistochemical analysis using cytokeratins. Clin Exp Dermatol 2009;34:406-8.
123. Yanagawa T, Yoshida H, Yamagata K, et al. Loss of cytokeratin 13 expression in squamous cell carcinoma of the tongue is a possible sign for local recurrence. J Exp Clin Cancer Res 2007;26:215-20.
124. Morifuji M, Taniguchi S, Sakai H, et al. Differential expression of cytokeratin after orthotopic implantation of newly established human tongue cancer cell lines of defined metastatic ability. Am J Pathol 2000;156:1317-26.